N-[(3R)-pyrrolidin-3-yl]benzamide | 850445-80-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(3R)-pyrrolidin-3-yl]benzamide
• CAS: 850445-80-6
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: FAVZGMWROXRERG-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[(3R)-pyrrolidin-3-yl]benzamide 、 N-carbethoxy-4-tropinone 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 生成 、
  参考文献：
  名称：

  Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor

  摘要：

  This Letter describes the continued optimization of the MLPCN probe molecule ML071. After introducing numerous cyclic constraints and novel substitutions throughout the parent structure, we produced a number of more highly potent agonists of the M-1 mACh receptor. While many novel agonists demonstrated a promising ability to increase soluble APP alpha release, further characterization indicated they may be functioning as bitopic agonists. These results and the implications of a bitopic mode of action are presented. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.088

文献信息

• [EN] IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS<br/>[FR] DÉRIVÉS D'IMIDAZOPYRAZINE EN TANT QU'ANTIBACTÉRIENS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020127075A1

  公开（公告）日：2020-06-25

  The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R14 are as described herein (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

  这项发明提供了具有通式（I）的新型咪唑吡嗪衍生物，其中A和R1至R14如本文所述（I），以及其药学上可接受的盐。还提供了包括这些化合物的药物组合物、制造这些化合物的方法以及将这些化合物用作药物的方法，特别是将这些化合物用作抗生素治疗或预防细菌感染及由此导致的疾病的方法。
• DPP-IV inhibitors
  申请人：Santhera Pharmaceuticals (Schweiz) GmbH

  公开号：EP1702916A1

  公开（公告）日：2006-09-20

  The invention relates to compounds of formula (I) wherein Z, R1-7, X and n have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式(I)的化合物，其中Z、R1-7、X和n的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及其作为药物的生产和使用。
• Dpp-Iv Inhibitors
  申请人：Edwards Paul John

  公开号：US20080275086A1

  公开（公告）日：2008-11-06

  The invention relates to compounds of formula (I) wherein Z, R 1-7 , X and n have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  本发明涉及公式（I）的化合物，其中Z，R1-7，X和n的含义如描述和权利要求所述。所述化合物可用作DPP-IV抑制剂。本发明还涉及制备这种化合物以及作为药物的生产和使用。
• IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3898629A1

  公开（公告）日：2021-10-27